Menu
Search Clinical Trials
Back to Search Results
Terminated
Astellas Study ID
3662-CL-0049

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects with Painful Diabetic Peripheral Neuropathy

Astellas Study ID
NCT02372578
Clinicaltrials.gov ID
NCT02372578
EUCTIS ID
N/A
EudraCT ID
N/A
jRCT ID
N/A
CN CDE ID
N/A
Get more information

Study summary

The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and tolerability of ASP3662 relative to placebo.

The analgesic effect is evaluated by measuring percent responders, change in daily worst pain score, change in average daily pain score, Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC).

Additional Study Details

Phase
2
Product
  • ASP3662
  • pregabalin
  • ASP3662 placebo
  • pregabalin placebo
    • Type
    Interventional
    Masking
    Triple (Participant, Investigator, Outcomes Assessor)
    Enrollment number
    115
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Download Document(s)
    Plain Language Summary
    Available Language(s): English
    Download Document(s)

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects with Painful Diabetic Peripheral Neuropathy? Contact us by filling out your information to the right and we’ll respond to you.

    • A caregiver
    • A healthcare provider
    • A parent
    • A patient
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Terminated
      Site US10064
      Metairie, LA, United States, 70006
      Contact Us
      Terminated
      Site US10036
      Chicago, IL, United States, 60624
      Contact Us
      Terminated
      Site US10013
      Kettering, OH, United States, 45429
      Contact Us
      Terminated
      Site US10063
      Quincy, MA, United States, 02169
      Contact Us
      Terminated
      Site US10014
      Duncansville, PA, United States, 16635
      Contact Us
      Terminated
      Site US10043
      Hazelwood, MO, United States, 63042
      Contact Us
      Terminated
      Site US10047
      Santa Monica, CA, United States, 90404
      Contact Us
      Terminated
      Site US10051
      Boston, MA, United States, 02115
      Contact Us
      Terminated
      Site US10003
      Oviedo, FL, United States, 32765
      Contact Us
      Terminated
      Site US10005
      Boynton Beach, FL, United States, 33436
      Contact Us
      Withdrawn
      Site US10030
      Medford, OR, United States, 97504
      Contact Us
      Terminated
      Site US10031
      San Antonio, TX, United States, 78228
      Contact Us
      Terminated
      Site US10009
      Aurora, IL, United States, 60506
      Contact Us
      Terminated
      Site US10039
      Phoenix, AZ, United States, 85023
      Contact Us
      Terminated
      Site US10033
      Salt Lake City, UT, United States, 84107
      Contact Us
      Terminated
      Site US10049
      The Villages, FL, United States, 32162
      Contact Us
      Terminated
      Site US10018
      Clearwater, FL, United States, 33765
      Contact Us
      Terminated
      Site US10046
      Orlando, FL, United States, 32806
      Contact Us
      Terminated
      Site US10001
      Anniston, AL, United States, 36207
      Contact Us
      Terminated
      Site US10025
      Evansville, IN, United States, 47714
      Contact Us
      Terminated
      Site US10026
      New Bedford, MA, United States, 02740-2133
      Contact Us
      Terminated
      Site US10020
      Lomita, CA, United States, 90717
      Contact Us
      Terminated
      Site US10019
      Deland, FL, United States, 32720
      Contact Us
      Terminated
      Site US10008
      Ormond Beach, FL, United States, 32174
      Contact Us
      Terminated
      Site US10054
      Fresno, CA, United States, 93720
      Contact Us
      Terminated
      Site US10041
      MiamiLakes, FL, United States, 33014
      Contact Us
      Withdrawn
      Site US10027
      Pasadena, MD, United States, 21122
      Contact Us
      Terminated
      Site US10004
      Homestead, FL, United States, 33030
      Contact Us
      Terminated
      Site US10053
      Fairfield, CT, United States, 06824
      Contact Us
      Terminated
      Site US10023
      Bradenton, FL, United States, 34205
      Contact Us
      Terminated
      Site US10032
      San Antonio, TX, United States, 78218
      Contact Us
      Terminated
      Site US10042
      Jacksonville, FL, United States, 32256
      Contact Us
      Terminated
      Site US10045
      Renton, WA, United States, 98057
      Contact Us
      Terminated
      Site US10034
      Austin, TX, United States, 78731
      Contact Us
      Terminated
      Site US10017
      Tustin, CA, United States, 92780
      Contact Us
      Terminated
      Site US10007
      Jupiter, FL, United States, 33458
      Contact Us
      Terminated
      Site US10055
      Walnut Creek, CA, United States, 94598
      Contact Us
      Terminated
      Site US10015
      Greer, SC, United States, 29651
      Contact Us
      Terminated
      Site US10040
      Houston, TX, United States, 77030
      Contact Us
      Trial info
      Follow Trial
      Age
      18 - 75 years
      Diamond icon
      Condition
    • Neuropathic Pain
      • Gender icon
      Sex
      Female & Male
      Calendar icon
      Trial Dates
      May 2015 - May 2016
      Additional Study Details
      Inclusion Criteria

        Inclusion Criteria:

      • Subject has a BMI ≤ 40.
      • Subject has all of the following:

        • a. Established diagnosis of diabetes (Type I or II) with painful diabetic peripheral neuropathy and glycosylated hemoglobin (HgbA1c) ≤ 9.5% at Screening or Randomization.

        b. Stable diabetic drug regimen for at least 3 months prior to Screening.

        c. At least a 1 year history of PDPN.

        d. Diagnosis of PDPN to be confirmed by a score of ≥ 3 on the Michigan Neuropathy Screening Instrument (MNSI) at Screening.

      • Subject has pain intensity score(s) ≥ 4 or ≤ 9 on an 11-point numeric pain rating scale (NPRS) at Screening Visit and prior to Randomization.
      • Subject agrees to complete pain diaries and is complaint with the daily pain recording prior to Randomization as defined by the completion of a minimum of 5 of 7 daily pain ratings, 3 of which are required in the last 4 days.
      • Subject's anti-diabetic regimen is anticipated to be stable throughout the study.
      • Subject must be willing to washout of all medications currently being taken for his/her PDPN (chronic and occasional/as needed) and remain off of those pain medications while participating in the study.

        • Exclusion Criteria:

      • Subject has received prior treatment with pregabalin for PDPN and was considered unresponsive or intolerant.
      • Subject has tried and failed 3 or more drugs to treat PDPN within the past 3 years. Drugs must have been administered at therapeutic doses and have been administered for an adequate period of time.
      • Subject has a known hypersensitivity to ASP3662, pregabalin, gabapentin or acetaminophen, or their formulation components.
      • Subject has significant pain (moderate or above) due to causes other than PDPN.
      • Subject has a history of painful peripheral neuropathy due to a cause other than diabetes.
      • Subject has any lower extremity amputation
      • Subject has a current or previous foot ulcer within the past 3 months as described by medical history and/or medical examination.
      • Subject has an active malignancy or a history of malignancy (except for treated non-melanoma skin cancer) within 5 years.
      • Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis, or a serum creatinine at Screening.
      • Subject has creatinine clearance < 60 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation) at Screening.
      • Subject tests positive for hepatitis B surface antigen (HBsAg) or hepatitis C antibody at Screening or has a known history of a positive test for human immunodeficiency virus (HIV) infection.
      • Subject has a positive drug screen for alcohol or drugs of abuse at Screening and/or Randomization. Subjects who are on low doses of benzodiazepines for sleep with a legitimate prescription will be allowed into the study. In addition, subjects with a positive drug screen at Randomization will be

        • excluded.

      • Subject is currently using protocol specified non-permitted medications including OTC products and is unable or does not choose to discontinue them.
      • Subject has planned an elective surgery during planned study participation.

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      Find a Trial
      2

      Why are Clinical Trials Important?

      Learn More
      3

      Why Participate in a Clinical Trial?

      Discover More

      For Your Information

      THE PURPOSE OF THIS WEBSITE IS TO OFFER EDUCATION AND INFORMATION TO PATIENTS AND THEIR FAMILIES AND FRIENDS, THE PUBLIC, AND HEALTHCARE PROFESSIONALS ABOUT THE CLINICAL TRIAL PROCESS. IN ADDITION, THE WEBSITE WILL PROVIDE SPECIFIC INFORMATION ABOUT ASTELLAS CLINICAL TRIALS. PLEASE READ THE COMPLETE ASTELLAS TRANSPARENCY POLICY TO LEARN ABOUT THE CLINICAL TRIAL INFORMATION AVAILABLE ON THIS WEBSITE